1. Home
  2. SWZ vs CRDF Comparison

SWZ vs CRDF Comparison

Compare SWZ & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Swiss Helvetia Fund Inc. (The)

SWZ

Swiss Helvetia Fund Inc. (The)

N/A

Current Price

$5.85

Market Cap

75.5M

Sector

Finance

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.72

Market Cap

67.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SWZ
CRDF
Founded
1986
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.5M
67.1M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
SWZ
CRDF
Price
$5.85
$0.72
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.28
AVG Volume (30 Days)
21.9K
★ 364.0K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 6.59%
N/A
EPS Growth
N/A
★ 27.37
EPS
★ N/A
N/A
Revenue
N/A
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$5.68
$0.72
52 Week High
$6.31
$3.31

Technical Indicators

Market Signals
Indicator
SWZ
CRDF
Relative Strength Index (RSI) 52.58 30.76
Support Level $5.74 N/A
Resistance Level $5.99 $1.13
Average True Range (ATR) 0.06 0.06
MACD 0.00 -0.00
Stochastic Oscillator 50.28 5.60

Price Performance

Historical Comparison
SWZ
CRDF

About SWZ Swiss Helvetia Fund Inc. (The)

Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: